We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Invltd Nm | 2005 | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | - |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| Top Posts |
|---|
Posted at 06/9/2005 22:06 by topbidd The perfect stormSep 6th 2005 From The Economist Global Agenda It's not just natural disasters that need preparing for: |
Posted at 28/4/2005 01:31 by mr ashley james Perfect Storm is Coming: in 2005 Maybe For the British and other European Monarchies quite clearly. Remember Mussolini? |
Posted at 30/1/2005 07:42 by mjneish Fickena, here's what a quick foray into Pharmagene has turned up; I've kept it as concise as possible. By all means exclude it from the header if it's too early-stage.Pharmagene [PGN] Web page: Development strategy: to achieve early-stage licensing and development partners for their therapeutic candidates. Discussions are underway for their four leading compounds. 2005 R1 for irritable bowel syndrome: entered Phase I in January 2005 R4 for migraine: to enter Phase I R65 for women's health, glaucoma and immunology: to enter pre-clinical trials R99 for inflammatory/immune disorders: pre-clinical candidate to be selected Pharmagene also has a drug discovery services division that is generating revenues. The share price is currently (end of January 2005) trading around cash level. |
Posted at 17/1/2005 14:18 by qazwsx123 Fickena I think your reference to CENES's: "CNS 3161 Phase II results due in H1 2005"; should actually refer to "CNS 5161 (neuropathic pain) Phase II results due in H1 2005". i.e. "5161", not "3161". |
Posted at 13/1/2005 13:47 by daimon Hello Fickena, I did some more digging regarding expected 2005 newsflow for Phytopharm and apart from the expected interim and final year figures which should show the progress of the ongoing sales of the two canine products, I discovered the following information from Phytopharm's website. I've pasted what should be the address for each particular page at the end of each section. Thanks for setting up this thread, it is very useful to collate so much relevant information in one readily avaialble and readable source. PYM 2005 expected info? Cogane Alzheimer's treatment. Mode of action In pre-clinical studies, the synthetic chemical Cogane, has been shown to be neuroprotective against beta-amyloid and glutamate damage, to reverse the decrease of neuronal growth factors and to reverse neuronal degeneration observed in the ageing brain. Importantly, this product restores levels of proteins that are altered in the ageing brain, returning them to levels observed in the young and causing beneficial neurite outgrowth and branching. In addition, Cogane restores the learning and memory ability in Alzheimer's disease models and thereby offers the potential to reverse the symptoms of Alzheimer's disease Progress to date The first clinical trial was conducted using a semi purified crude extract. The key findings showed that the 30 patients treated over the 3-month trial significantly improved their mini-mental state estimate (MMSE) score. The first phase I trial using Cogane investigated the safety, tolerability and pharmacokinetics in healthy volunteers. The second phase I trail examined repeat doses to healthy elderly volunteers for 7 days followed immediately by a 28-day trial. In November 2003 Phytopharm reported the successful completion of this study demonstrating that Cogane has absorption and pharmacokinetic characteristics suitable for once daily dosing and is well tolerated with a good emergent safety profile. In December 2003, we announced that we had been granted clearance by the Medicines and Healthcare Products Regulatory Agency (MHRA) to commence a phase II 'proof of principle' clinical study in Alzheimer's disease patients under a clinical trial exemption (CTX) certificate. The study utilises a randomised, double blind placebo-controlled design to evaluate the safety, efficacy and pharmacokinetic profile of Cogane after once daily oral administration over 3 months. The effects of Cogane on memory, concentration and executive function will be evaluated during the study. The study is expected to report in H2 2005 Asthma and other inflammatory diseases. Preclinical stage Programme: P61 Asthma is a chronic inflammatory disorder of the airways. Approximately 8 million people in the UK have been diagnosed with asthma, and the condition costs the NHS on average £850 million per year (Source: Asthma UK). Asthma causes recurrent episodes of wheezing, breathlessness, chest tightness and cough. In addition, asthma is usually associated with widespread but variable airflow obstruction. Inhibition of inflammation and relaxation of airway smooth muscle are therefore key components of asthma treatment. Mode of action A number of lead compounds have been synthesised, demonstrating anti-inflammatory and anti-spasmodic activity in several established models of asthma and inflammation. Progress to date The mechanism of action and structure activity relationships are being developed and patented. We anticipate the lead candidate ready for development within 2005. |
Posted at 12/1/2005 14:48 by s h b fickenaYes CBF is a UK listed Biopharma manufacturer, is a good recovery play for 2005. also you might like to check out this comprehensive report for whats in store for Biotech in 2005. December 22, 2004 Burrill's Biotech Outlook for 2005 |
Posted at 09/1/2005 22:00 by qazwsx123 Fickena (Post 29) my comment about the revised timetable for a deal on OXB's Trovax represents the latest know news and was published this Friday 7/1/2005 in Investors Chronicle (p28); a known third party. As such, your information for OXB's Trovax (quote "commercial collaboration") is misleading without it. You need to keep the information up to date, otherwise it will be useless. Obviously, if a Company gives an interview (as apparently, in the case of OXB regarding Trovax) in which they disclose new information about potential timetabling or trial funding, it is important to include such information. The key thing is to mention a reference, then people can decide for themselves. .................... Investors Chronicle 7th January 2005 (p28): Oxford Biomedica: Trovax: "...the drug has not yet found a partner and Oxford Biomedica is considering funding a Phase III trial itself". .................... As such, one might conclude the following: 1) OXB may fund lead Trovax PIII's themselves, so a deal for Trovax still appears be some years away. 2) If OXB fund PIII Trovax themselves, it would seem logical for them to stage a share issue soon in order to raise cash to fund the trials. 3) An earlier deal would probably not provide the kind of terms which OXB seek, i.e. would be comparatively small. |
Posted at 08/1/2005 11:54 by fickena Mj,I was thinking along the same lines. I think the title will soon be obsolete as well, so I was thinking something along the lines of "Biotech Targets for 2005" or "Biotech Targets and Milestones for 2005" etc So once it gets going then I will start a new thread and copy all the progress tables across. It regards to the logos I also agree, just wanted to give it some wow factor to start with to gain interest and then hopefully I would like to include a small 2005 chart be the side of each company to help show the link (or not) of expected news flow, news and price changes. I need some more input though. I have someone working on MLB info, but I thought the OXB lot would be clambering to get theirs up, but nothing yet. There is a least 100 biotechs around, so I am surprised I haven't had more suggested yet. |
Posted at 29/12/2004 22:17 by paulismyname E, I do not disagree with some of the theory of what you say especially about China and commodity stocks but I would point out the (charts, performance, and markets) of commodities does not match your view.If you look at UB04 (FT350 Mining stocks) you will see that through the whole of 2004 on a buy and hold basis from January to December you would have made no money. And in addition if you used finance (CFD leverage etc) you would have lost due to interest costs. I also note that I have been told China is seeking to restrain growth to avoid creating a bubble (especially with their banking system. It is fair to say that some small cap penny share mining companies may have broken that general negative trend but on the whole this has been due to discoveries of assets, which have impacted favourably on the NAV. However gambling on penny share mining stocks is the fastest way to get poor or rich quick.... rather than a more sensible buy and hold in a range trade scenario delivering safer profits and peace of mind. Also I would point out that in the UK the FT100 is hardly in crash mode being on an average PE ratio of around 15, with a dividend yield of 3.2% and cover of around 2.2.... indeed a case could be argued that to reflect more longer term trends there may be 20% upside to today's closing price of 4819. I agree an unexpected terror incidents or debt crisis may alter that more easy going view. But again most major economic news is "in the price" as they say, even the mortgage issues of Fanny and Freddy in the USA had little impact on the markets last week. |
Posted at 23/12/2004 09:43 by energyi MARKETOCRACY has a thread with Views of 2005.I liked this one for its simplicity: AUTHOR: moydodyr RANK: Top Return DATE: Dec 22, 2004 PAST RANK: My outlook for 2005 is pretty much unchanged. All the themes we had in 2004 are still here, even more pronounced now. - if you produce what China produces, you lose - if you produce what China needs, you win - american consumer is still spending beyond his means - the american gubmint is still spending beyond their means - the war is still going on with no end in sight - commodity inflation is here and accelerating - the dollar is weak - the stocks are overbought - the bonds are overbought - real estate is overbought we had this situation a year ago and nothing really changed. Yet. Expect more of the same themes that gave me a 35% investment return this year: - bet on all commodities, from meat to copper - bet against the US dollar - bet on energy and water - bet on asia - bet on south america and east europe - bet on dividend payers - stay away from T-bills, real estate and Nasdaq and you'll do just fine :o) @: |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
